de Verneuil Vanina, an officer at Vir Biotechnology, Inc., has sold 2,407 shares of the company's common stock, according to a recent SEC filing. This transaction, valued at approximately $26,717.70, occurred on November 3, 2026, following the vesting of restricted stock.

This sale is significant as it reflects ongoing trends in the biotechnology industry, where executive compensation often includes stock options and restricted shares. Such transactions can impact investor perceptions regarding the stability and confidence of company leadership.

Background

Vir Biotechnology, Inc. is a company focused on developing therapies for infectious diseases and other serious conditions. It operates within the biological products sector, specifically categorized under the SIC code for Biological Products (No Diagnostic Substances). The company is publicly traded on the NASDAQ under the SEC file number 001-39083.

What the Filing Says

The SEC filing indicates that de Verneuil Vanina acquired the 2,407 shares through restricted stock vesting on November 1, 2026. The filing states, "Nature of Acquisition Transaction: Restricted Stock Vesting." This transaction was facilitated through Fidelity Brokerage Services LLC.

Impact

This sale may affect investor sentiment towards Vir Biotechnology, especially as it involves a high-ranking officer. The total number of shares outstanding is reported at 169,215,958, indicating that this transaction represents a small fraction of the company's total equity. However, it may raise questions about the motivations behind the sale and its timing.

What's Next

The filing does not say what happens next.